ATE348617T1 - Heilmittel gegen durch endothelin verursachte erkrankungen - Google Patents

Heilmittel gegen durch endothelin verursachte erkrankungen

Info

Publication number: ATE348617T1
Authority: AT; Austria
Prior art keywords: endothelin; remedies; diseases caused; diseases; caused
Prior art date: 2000-02-16

Application number

AT00970160T

Other languages

English (en)

Inventor

Hironori Yuyama

Akira Fujimori

Masanao Sanagi

Hironori Harada

Akiko Koakutsu

Mikiko Mori

Nobuyuki Yamamoto

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-16

Filing date

2000-10-27

Publication date

2007-01-15

2000-10-27 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE348617T1 publication Critical patent/ATE348617T1/de

Links

102000002045 Endothelin Human genes 0.000 title 1
108050009340 Endothelin Proteins 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00970160T 2000-02-16 2000-10-27 Heilmittel gegen durch endothelin verursachte erkrankungen ATE348617T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000037313		2000-02-16
JP2000037314		2000-02-16

Publications (1)

Publication Number	Publication Date
ATE348617T1 true ATE348617T1 (de)	2007-01-15

Family

ID=26585418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00970160T ATE348617T1 (de)	2000-02-16	2000-10-27	Heilmittel gegen durch endothelin verursachte erkrankungen

Country Status (15)

Country	Link
US (1)	US6774131B1 (de)
EP (1)	EP1256344B1 (de)
JP (2)	JP3832229B2 (de)
KR (1)	KR20020075797A (de)
CN (1)	CN1434715A (de)
AR (1)	AR031679A1 (de)
AT (1)	ATE348617T1 (de)
AU (1)	AU2000279614A1 (de)
BR (1)	BR0017120A (de)
CA (1)	CA2395711A1 (de)
DE (1)	DE60032517T2 (de)
ES (1)	ES2277856T3 (de)
HU (1)	HUP0204139A3 (de)
RU (1)	RU2002124599A (de)
WO (1)	WO2001060370A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
GB0219660D0 (en)	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
CN104288119A (zh) *	2007-02-09	2015-01-21	英卡塔有限公司	稳定化的吡铂口服剂型
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
TW200920347A (en) *	2007-07-16	2009-05-16	Poniard Pharmaceuticals Inc	Oral formulations for picoplatin
AU2009210654A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
WO2009141167A1 (en) *	2008-05-23	2009-11-26	Synthon B.V.	Bosentan salts
CA2888122A1 (en)	2012-10-12	2014-04-17	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
US10119171B2 (en)	2012-10-12	2018-11-06	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100456650B1 (ko)	1995-12-20	2005-06-20	야마노우치세이야쿠 가부시키가이샤	아릴에텐설폰아미드유도체
US6030975A (en) *	1997-03-14	2000-02-29	Basf Aktiengesellschaft	Carboxylic acid derivatives, their preparation and use in treating cancer
US6673832B1 (en) *	1998-05-04	2004-01-06	Gudarz Davar	Methods for identifying compounds for treating pain

2000
- 2000-10-27 DE DE60032517T patent/DE60032517T2/de not_active Expired - Fee Related
- 2000-10-27 AR ARP000105669A patent/AR031679A1/es not_active Application Discontinuation
- 2000-10-27 ES ES00970160T patent/ES2277856T3/es not_active Expired - Lifetime
- 2000-10-27 HU HU0204139A patent/HUP0204139A3/hu active IP Right Revival
- 2000-10-27 AT AT00970160T patent/ATE348617T1/de not_active IP Right Cessation
- 2000-10-27 RU RU2002124599/15A patent/RU2002124599A/ru not_active Application Discontinuation
- 2000-10-27 CA CA002395711A patent/CA2395711A1/en not_active Abandoned
- 2000-10-27 KR KR1020027010589A patent/KR20020075797A/ko not_active Withdrawn
- 2000-10-27 EP EP00970160A patent/EP1256344B1/de not_active Expired - Lifetime
- 2000-10-27 BR BR0017120-4A patent/BR0017120A/pt not_active IP Right Cessation
- 2000-10-27 AU AU2000279614A patent/AU2000279614A1/en not_active Abandoned
- 2000-10-27 CN CN00818938A patent/CN1434715A/zh active Pending
- 2000-10-27 JP JP2000328374A patent/JP3832229B2/ja not_active Expired - Fee Related
- 2000-10-27 US US10/181,489 patent/US6774131B1/en not_active Expired - Fee Related
- 2000-10-27 WO PCT/JP2000/007573 patent/WO2001060370A1/ja not_active Ceased
2006
- 2006-03-29 JP JP2006090667A patent/JP2006176542A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2000279614A1 (en)	2001-08-27
RU2002124599A (ru)	2004-03-10
HUP0204139A2 (en)	2003-05-28
BR0017120A (pt)	2003-01-14
DE60032517D1 (de)	2007-02-01
US6774131B1 (en)	2004-08-10
KR20020075797A (ko)	2002-10-05
CA2395711A1 (en)	2002-07-18
AR031679A1 (es)	2003-10-01
ES2277856T3 (es)	2007-08-01
JP3832229B2 (ja)	2006-10-11
HUP0204139A3 (en)	2003-07-28
EP1256344B1 (de)	2006-12-20
JP2006176542A (ja)	2006-07-06
DE60032517T2 (de)	2007-10-04
EP1256344A4 (de)	2004-12-29
EP1256344A1 (de)	2002-11-13
CN1434715A (zh)	2003-08-06
JP2001302514A (ja)	2001-10-31
WO2001060370A1 (en)	2001-08-23

Legal Events

Date	Code	Title	Description
2007-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
AR028204A1 (es)	2003-04-30	Composiciones farmaceuticas electrohiladas
FI20105657L (fi)	2010-06-10	Farmaseuttisia koostumuksia
IS6686A (is)	2003-01-16	Hýdrógel-drifið lyfjaskömmtunarform
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
DK1524266T3 (da)	2007-06-25	Farmaceutisk sammensætning
NO20052306D0 (no)	2005-05-11	Dispergerbare farmasoytiske blandinger.
EE200200387A (et)	2003-10-15	Fulvestrandi formulatsioonid
ATE311915T1 (de)	2005-12-15	Medikamentenspender
NO20026175L (no)	2003-02-26	Vaksinesammensetning
DE60232949D1 (de)	2009-08-27	Lung durch ballastflockung
PL364773A1 (pl)	2004-12-13	Inhalator dozujący ksynafonian salmeterolu
DE60044147D1 (de)	2010-05-20	Knetvorrichtung
EP1310252A4 (de)	2009-06-10	Injektionen
DE60205322D1 (de)	2005-09-08	Fluoroelastomere
DE60032517D1 (de)	2007-02-01	Heilmittel gegen durch endothelin verursachte erkrankungen
NO20026123L (no)	2003-02-18	Farmasöytiske sammensetninger
ITMI20000901A0 (it)	2000-04-21	Fluoroelastomeri
DE50209245D1 (de)	2007-02-22	Neuroprotektives medikament
NO20031095L (no)	2003-03-10	Farmasoytiske sammensetninger
DE60229463D1 (de)	2008-12-04	Fluoroelastomere
NO20035352L (no)	2004-02-19	Legemidler for eosinofile sykdommer
NO20031650L (no)	2003-06-05	Nye legemidler for leversykdommer
NO20032957L (no)	2003-08-28	Farmasöytisk emulsjonspreparat
DK200000305U3 (da)	2002-02-22	Ultralydapparat
FI20001146L (fi)	2001-10-27	Z-kampimekanismi